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Matrix metalloproteinase 8 (MMP-8) is the most potent type-I collagen protease. Such colla-
gen mainly constitutes the transient fibrosis in takotsubo cardiomyopathy (TTC) endomyo-
cardial biopsies. High MMP-8 and tissue-inhibitor of matrix metalloproteinase-1 (TIMP-1)
levels are implicated in acute coronary syndrome (ACS). We compared MMP-8 and TIMP-1
levels in consecutive TTC and ACS patients, and their association to TTC severity.
Methods and results
In 45 acute serum samples of TTC, 2072 ACS and 1000 controls, TIMP-1 differed between
ACS 146.7ng/mL (115.0–186.3) (median (interquartile range)), TTC 115.7 (94.3–137.7) and
controls 80.9 (73.2–90.4), (p<0.0001). MMP-8 levels were similar between ACS and TTC.
In receiver-operating characteristics analysis, TIMP-1 differentiated TTC from ACS with an
area under the curve (AUC) of 0.679 (p<0.0001) surpassing troponin T (TnT) at 0.522 (p =
0.66). Compared to other differing factors (age, sex, smoking), TIMP-1 improved diagnostic
specificity and sensitivity from AUC of 0.821 to 0.844 (p = 0.007). The MMP8/TIMP-1 molar
ratio differentiated normal ejection fraction (EF) at 0.27 (0.13–0.51) from decreased
EF<50% at 0.08 (0.05–0.20), (p = 0.04) in TTC, but not in ACS.
Conclusions
Even with other differing factors considered, TIMP-1 differentiated TTC from ACS better
than TnT. In TTC, the low MMP-8/TIMP-1 molar ratio may reflect decreased proteolysis and
increased transient fibrosis, perhaps in part explaining the left-ventricle impairment.
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Introduction
Takotsubo cardiomyopathy (TTC), a form of acute heart failure, mimics myocardial infarction
with similar electrocardiogram and cardiac enzyme findings [1]. In an acute setting, the TTC
and acute coronary syndrome (ACS) are difficult to distinguish without an invasive procedure.
Coronary angiograms of TTC patients show no signs of occlusive coronary artery disease, and
left ventriculograms reveal a typical transient contraction abnormality which usually resolves
within weeks. Previous attempts to differentiate TTC from ACS using current non-invasive
methods such as ECG, cardiac enzymes, or acute-phase reactants such as C-reactive protein
resulted in inadequate resolution and controversy [2,3].
Matrix metalloproteinases (MMPs) maintain extracellular matrix (ECM) under normal
conditions with their ability to cleave almost all extracellular proteins such as collagens. Struc-
turally related MMPs are secreted mainly by inflammatory cells, but also by endothelial and
smooth muscle cells [4]. MMP activity is tightly controlled by tissue inhibitors of matrix metal-
loproteinases (TIMPs) [5,6]. Disturbance in MMP and TIMP balance may raise or lower the
ECM fibrotic material and accompany inflammation. Such changes, especially in MMP-8 and
TIMP-1 levels, accompany the pathogenesis of atherosclerosis and acute coronary syndrome
[6–9]. In myocardial ECM, an altered MMP and TIMP balance may lead to structural and
functional changes, and subsequent impairment of cardiac function as seen in heart failure
and various cardiomyopathy patients [10,11].
Left ventricle presentation in TTC varies from normal ejection fraction (EF) to cardiogenic
shock. Factors affecting the severity of contraction abnormality and heart failure in TTC are
unknown [12]. Endomyocardial biopsies of acute TTC patients show transient ECM fibrosis
[13]. Altered fibrosis due to MMP-8 and TIMP-1 imbalance may play a role in pathogenesis.
Reports of small TTC patient-series showed similar MMP and TIMP profiles as in hyperten-
sion- and diastolic heart-failure patients, but include no direct comparisons to ACS [14].
We set out to compare the levels of circulating MMP-8 and TIMP-1 between acute ACS-,
TTC-, and control patients. The aim was to improve non-invasive methods to differentiate
ACS from TTC. We also aimed to discover whether their serum TIMP-1 and MMP-8 levels
correlate with severity or variant of the contraction abnormality in TTC, and thus may play a
role in the underlying pathophysiology.
Methods
Study populations
The study population comprised 2167 consecutive acute cardiac patients from the large COR-
OGENE study [15]. In brief, 5294 patients were each assigned to undergo a coronary angio-
gram (CAG) in Helsinki University Hospital between June 2006 and March 2008. The data
register is based on comprehensive patient-specific data incorporating medical records and a
2-page questionnaire with information on medical history, demographics, co-morbidities, cur-
rent condition, cardiovascular risk factors, and on medications such as antihypertensive or
lipid-lowering drugs. Results were included from electrocardiograms, echocardiograms, and
coronary angiograms.
Acute coronary syndrome (ACS) was defined as an episode of typical chest pain for ische-
mia and>50% stenosis in 1 coronary artery. The electrocardiogram had to show typical
ischemic changes for unstable angina pectoris (UAP), non–ST-elevation myocardial infarction
(NSTEMI), or ST-elevation myocardial infarction (STEMI). The distribution of patients with
ACS was as follows: with STEMI, 722 (35%), with NSTEMI, 1123 (54%), and with UAP, 226
(11%). All ACS patients were treated with standard drug regimens and procedures. The
remaining 95 acute patients were further reviewed, and 45 met the following criteria for TTC:
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1. acute chest pain or dyspnea or both; 2. acute ST-T changes in electrocardiogram or elevated
cardiac enzymes or both; 3. absence of obstructive coronary artery disease (< 50% luminal
narrowing); 4. myocarditis excluded. The 50 excluded patients had other cardiac or non-car-
diac condition such as atrial fibrillation.
For TTC patients, following an angiogram, a left ventriculogram was performed with the
Siemens AXIOM Artis dFC system and EF, end diastolic volume, end systolic volume, and
stroke volume were measured with Siemens AXIOM Sensis software (Siemens AG, Forcheim,
Germany). Involvement of apical myocardium determined the TTC subtype: the left ventricle
was divided into apical 30%, mid- 35%, and basal 35% portions by adapting a method previ-
ously described for tomographic imaging of the heart [16]. Based on a clinical decision, ACS
patients’ echocardiograms were performed during their hospitalization, and the EF informa-
tion came from their medical records.
FINRISK is a population-based survey designed for study of the prevalence in Finland of
cardiovascular disease (CVD) risk factors [17,18]. The 1997 survey included 8389 randomly
selected Finnish men and women aged 25 to 74 years. Participants underwent a physical
examination and completed a questionnaire regarding cardiovascular risk factors and doc-
tor-diagnosed diseases. Controls in the present study were chosen from among the partici-
pants of the FINRISK in the same region—Helsinki and Uusimaa—as the patients in the
COROGENE. After exclusion of those with prevalent or incident CVD events, prevalent or
incident diabetes, and those with prevalent metabolic syndrome [19], the population com-
prised 1000 healthy subjects. Information on CVD events and diabetes was complemented
with register data either as hospitalizations with the disease or as intake of related drugs. The
incident diseases were excluded based on 13 years of follow-up. Metabolic syndrome was
defined based on clinical examination, intake of drugs in connection to the diagnosis, and
laboratory determinations.
The COROGENE study was approved by the ethics committee of the University of Helsinki
and the FINRISK study by the ethics committee of the National Institute of Health and Wel-
fare. The investigation conforms with the principles outlined in the Declaration of Helsinki.
Written informed consent came from each of the subjects.
Laboratory determinations
Blood samples from the Corogene population were acquired in the beginning of CAG from an
arterial cannula. Citrated plasma was stored at –80˚C until analyzed. High-sensitivity C-reac-
tive protein (hsCRP) (Orion Diagnostica, Espoo, Finland) and Troponin T (TnT) (Roche
Diagnostics GmbH, Basel, Switzerland) were both measured upon admission according to the
laboratory standards of Helsinki University Hospital. In addition, the highest value of TnT
during hospitalization was recorded.
Blood samples from the FINRISK population were collected during clinic visits. The partic-
ipants were asked to fast for 4 hours and to avoid heavy meals before the blood sampling. The
median fasting time was 5 (interquartile range 3–7) hours. All laboratory measurements were
carried out at the Disease Risk Unit of the National Institute for Health and Welfare, Helsinki,
and are described elsewhere in detail [20].
Serum MMP-8 concentrations were determined by a time-resolved immunofluorometric
assay (IFMA) and TIMP-1 concentrations by enzyme-linked immunosorbent assay (ELISA;
R&D Systems, Minneapolis, MN, USA) from both study populations, as described [21]. The
inter-assay coefficient of variation (CV) for MMP-8 IFMA was 7.3% (28 subjects), and the
detection limit was 0.08 μg/l. The inter-assay CV% for TIMP-1 ELISA was 8.2% (28 subjects),
and the detection limit was 0.08 ng/ml [21].
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Statistical and data analysis
Statistical analyses were performed with SPSS v. 21.0 (SPSS Inc., Chicago, IL, USA). Signifi-
cance of the differences in the characteristics between cases and controls, and within TTC
patients, underwent analysis depending on the normality and size of the study groups by Stu-
dent’s t-test or the Mann-Whitney U-test for the continuous variables and by Chi-square for
the categorical variables. Data distribution was assessed with Kolmogorov-Smirnov and Sha-
piro-Wilk tests as well as visually inspected with Q-Q plots and histograms. Relationships
between study covariates were tested with Pearson correlation or Spearman’s rho within cases
and controls separately. To study the diagnostic ability of MMP-8, TIMP-1, and MMP-8/
TIMP-1 molar ratio to distinguish cases from controls, receiver-operating characteristics
(ROC) was the test used. Parameters with skewed distribution were log-transformed prior to
analysis. To assess whether these determinations had value over the traditional risk factors, C-
statistics were included in the analysis. A multivariate logistic model adjusted for age, sex,
smoking, high-density lipoprotein (HDL), body mass index (BMI), dyslipidemia, diabetes, and
hypertension served to analyse the associations between the tertiles of the concentrations and
diagnoses. A p-value less than 0.05 was considered statistically significant. Depending on dis-
tribution, values are expressed either as mean ± standard deviation (SD) or median (interquar-
tile range (IQR)). Confidence intervals (CIs) and odds ratios (ORs) are presented when
applicable.
Results
The acute patients, with ACS or TTC, were of similar age, but averaged somewhat older than
controls. Male dominance was observable in the ACS group (69.4%), as opposed to female
dominance in the TTC group (86.7%). In controls, the distribution was almost equal (male
44.8%). Among the cardiovascular risk factors, the controls had a lower BMI than did those
with ACS or TTC. Hypertension was less frequent in controls and smoking most frequent
among ACS patients. Total cholesterol and LDL cholesterol levels were highest in the control
patients; the HDL cholesterol levels were lowest in the ACS group. Medication was similar for
those with TTC or ACS (Table 1).
As expected, acute-phase protein HsCRP-, as well as cardiac enzymes TnT- and CK-MBm
levels were higher in ACS and in TTC patients than in controls. Of the four, ACS and TTC
patients differed only in the highest in-hospital TnT level (Table 1, Fig 1D). In TTC patients,
hsCRP correlated with MMP-8 (r = 0.4; p = 0.006) and TIMP-1 (r = 0.3; p = 0.03), but not with
TnT. In ACS patients, MMP-8 and TIMP-1 correlated with hsCRP (both r = 0.3; p< 0.001).
Moreover, ACS patients’ TnT showed a weak correlation with MMP-8 and MMP-8/TIMP-1
molar ratio (r< 0.16; p< 0.001).
TTC and ACS patients had similar MMP-8 levels, which were higher than those of the con-
trols. TIMP-1 levels, however, were highest in ACS patients, followed by the TTC- and control
levels (p< 0.0001, for both) (Table 1, Fig 1A and 1B). When patients were divided into tertiles
according to serum levels of MMP-8, TIMP-1, and MMP-8/TIMP-1 molar ratio respectively,
the TIMP-1 was associated with ACS over TTC, as the 3rd vs 1st tertile OR 4.52 (1.86–11.00;
p< 0.002), but MMP-8 and MMP-8/TIMP-1 molar ratio did not. (S1 Table). The association
of TIMP-1 with ACS remained statistically significant in multivariate analysis (Table 2).
The sensitivity and specificity of the TIMP-1 in differentiation of ACS from TTC in ROC
analysis showed an area under the curve (AUC) of 0.679 (95% CI 0.606–0.753; p< 0.0001)
(Fig 1E). In the c-statistics, TIMP-1 raised the sensitivity and specificity over the other signifi-
cant differences (age, sex, and smoking) (p< 0.01) improving the AUC from 0.821 (95% CI
0.764–0.879; p< 0.0001) to 0.844 (95% CI 0.783–0.906; p< 0.0001) (Fig 1F).
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The MMP-8 and MMP-8/TIMP-1 molar ratio also produced significant results (p< 0.0001),
but AUC’s were similar to those comprising age, sex, and smoking (Table 2). Controls were dif-
ferentiated from TTC clearly by MMP-8, TIMP-1 (p< 0.0001) and MMP-8/TIMP-1 molar
ratio (p< 0.05).
Median EF in TTC patients was 53% (IQR 35–62), and 17 patients had low EF< 50%. Such
patients had low MMP-8 levels, but high TIMP-1 levels compared to TTC patients with nor-
mal EF (S2 Table, Fig 2). EF correlated with MMP-8/TIMP-1 molar ratio (r = 0.358, p = 0.02),
but not separately with MMP-8 or TIMP-1. In TTC, hsCRP correlated with MMP-8 and
TIMP-1 (r> 0.3; p < 0.05). Left ventricular volumes (end-diastolic, end-systolic, or stroke vol-
ume) failed to correlate with MMP-8, TIMP-1, or MMP-8/TIMP-1 molar ratio. In ACS
patients, neither MMP-8 nor TIMP-1 was related to EF (Fig 2). TTC patients with EF < 50%
had similar TIMP-1, but lower MMP-8 levels than ACS patients. Normal EF> 50% TTC
patients had lower TIMP-1 and similar MMP-8 levels than those with ACS (S2 Table, Fig 2).
Apical TTC patients had lower EF and higher cholesterol levels than did those with mid-
ventricular TTC, but showed no differences in their cardiac enzymes, acute phase reactants,
MMP-8, TIMP-1, or their MMP-8/TIMP-1 molar ratios (S3 Table).
Table 1. Patient characteristics in case-control sample.
ACS TTC Control p-value
n = 2072 n = 45 n = 1000 1 and 2 1 and 3 2 and 3
Age 66 ± 12 66 ± 9 44.7 ± 13 0.810 <0.001 <0.001
BMI 27.4 ± 4.8 26.4 ± 4.8 25.0 ± 3.5 0.167 <0.001 0.063
Smoking, ever 1305 (63.0) 18 (40.0) 404 (40.4) 0.003 <0.001 0.957
Hypertension 1365 (65.9) 27 (60.0) 319 (31.9) 0.429 <0.001 <0.001
Diabetes 396 (19.1) 6 (13.3) 0 (0.0) 0.328 <0.001 <0.001
Hyperchol or statin 1187 (57.3) 23 (51.1) 690 (69.0) 0.448 <0.001 0.014
Total cholesterol (mmol/L) 4.3 ± 1.1 4.5 ± 0.8 5.4 ± 1.0 0.516 <0.001 <0.001
LDL (mmol/L) 2.4 ± 0.4 2.2 ± 0.7 3.4 ± 0.9 0.148 <0.001 <0.001
HDL (mmol/L) 1.2 ± 0.4 1.7 ± 0.6 1.5 ± 0.3 <0.001 <0.001 0.003
Triglyceride 1.2 (0.9–1.7) 1.2 (0.8–1.5) 1.0 (0.8–1.4) 0.195 <0.001 0.405
Pro-BNP 2034 (681–6013) 4478 (411–13291) N/A 0.67 N/A N/A
ACE-inhibitor 478 (23.1) 10 (22.2) N/A 0.819 N/A N/A
AT-blocker 304 (14.7) 7 (15.6) N/A 0.917 N/A N/A
Statin medication 750 (36.2) 14 (31.1) 12 (1.2) 0.36 <0.001 <0.001
Thrombolysis 246 (11.9) 0 (0.0) N/A 0.014 N/A N/A
TnT admission (μg/L) 0.3 (0.1–0.9) 0.2 (0.1–0.6) N/A 0.657 N/A N/A
TnT highest (μg/L) 0.84 (0.26–2.47) 0.32 (0.17–0.69) N/A <0.001 N/A N/A
CK-mbm (μg/L) 8.0 (4.0–26.0) 11.0 (6.0–16.0) N/A 0.508 N/A N/A
hsCRP (mg/L) 5.8 (1.9–20.5) 6.5 (1.9–21.7) 0.8 (0.4–1.9) 0.886 <0.001 <0.001
TIMP-1 (ng/mL) 146.7 (115.0–186.3) 115.7 (94.3–137.7) 80.9 (73.2–90.4) <0.001 <0.001 <0.001
MMP-8 (ng/mL) 61.5 (29.2–125.4) 58.7 (25.7–130.4) 26.3 (14.9–48.2) 0.847 <0.001 <0.001
MMP-8/TIMP-1 0.18 (0.08–0.37) 0.21 (0.08–0.46) 0.14 (0.08–0.26) 0.314 <0.001 0.012
ACE, angiotensin convertase enzyme; ACS, acute coronary syndrome; AT, angiotensin; BMI, body mass index; CK-mbm, creatine kinase mb-mass; HDL,
high-density lipoprotein; hsCRP, high sentivity c-reactive protein; LDL, low-density lipoprotein; MMP-8, matrix metalloproteinase 8; Pro-BNP, beta-
natriuretic propeptide; TIMP-1, tissue inhibitor of matrixmetalloproteinase; TnT, troponin T; TTC, takotsubo cardiomyopathy. Data as n (%),
mean ± standard deviation or median (interquartile range). Hypercholesterolemia: total >5.0 or LDL >3.0. N/A, not available
doi:10.1371/journal.pone.0173371.t001
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Discussion
We analysed levels of the most potent collagen type-I degrading protease, MMP-8 [22], and of
its inhibitor TIMP-1 levels in acute-phase TTC and ACS patients as well as in healthy controls.
To discover whether these levels could differentiate TTC patients from ACS patients, we
showed that TIMP-1 level differed significantly between these study groups. Moreover, TIMP-
1 could segregate TTC from ACS better than TnT could, even with other differing factors
(age, sex, and smoking) considered. Furthermore, the MMP-8/TIMP-1 ratio correlated with
TTC patients’ EFs. This association may reflect increased fibrosis and thus the left ventricle
impairment severity.
Even though TnT shows high specificity for myocardial damage, the slow elevation of TnT
concentrations causes problems in acute decision-making. Furthermore, other non-athero-
sclerotic heart conditions, like TTC, may also cause TnT elevation, making all attempts to
improve the diagnostics in ACS-suspected patients worthwhile.
Collagen, especially type I, is a key load-bearing protein in the ECM of atherosclerotic pla-
ques. Measurements both from ACS patients’ circulation and from their vulnerable atheroscle-
rotic plaques show elevated levels of MMP-8, which seems to play a role in thinning of the
atheroma-protective cap by cleaving the supportive type-I-collagen [4]. TIMP-1 has a high
specificity to MMP-8; and in addition to MMP inhibition, independently exerts pro-inflam-
matory and growth factor-like properties [23]. TIMP-1 is also elevated in ACS patients’ serum
Fig 1. Differences in acute-phase levels of A) matrix metalloproteinase-8 (MMP-8), B) tissue inhibitor of matrix metalloproteinase-1 (TIMP-
1), and C) MMP-8/TIMP-1 molar ratio of acute coronary syndrome (ACS) (n = 2072) and takotsubo cardiomyopathy (TTC) (n = 45)
compared to those of controls. D) Troponin T on admission and highest value during hospitalization in ACS and TTC. E) ROC curves of
TIMP-1 and troponin T in differentiation of ACS from TTC. F) ROC curves after c-statistics showing the improved ability of TIMP-1 + other
differing factors (age, sex and smoking) in differentiation between TTC and ACS over other differing factors alone (Table 2). Data in box-
plots are presented as medians, 25th and 75th percentiles (boxes), and 10th and 90th percentiles (whiskers).* p < 0.001; ** p = 0.01.
doi:10.1371/journal.pone.0173371.g001
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samples [6]. Elevated MMP-8 and TIMP-1 levels, resulting from rupture of atherosclerotic pla-
que, thus have the potential to differentiate between ACS and TTC.
In the current study, ACS and TTC patients’ MMP-8 and TIMP-1 profiles differed. Their
levels were higher in TTC and ACS patients relative to those in controls, indicating their
involvement in both acute conditions. TIMP-1 differentiated ACS from TTC with higher sen-
sitivity and specificity than did the classic myocardial damage-marker TnT. Stratification of
the groups by age and by their significant clinical differences (age, sex, and smoking) enhanced
this result. Conclusively, in an acute cardiac condition, low TIMP-1 and TnT levels suggest
TTC rather than ACS.
The exact pathophysiology of TTC remains an open question. Thus far, the most plausible
mechanisms seem to be a catecholamine surge accompanied by a change in adrenergic signal-
ling, [24] and a microvascular dysfunction [25]. Whether their effects are mutually exclusive
or synergetic is unknown [12].
Change in ECM composition is the key element of the left-ventricle remodelling found in
TTC patients’ acute phase and post-recovery endomyocardial biopsies. These biopsies show a
transient increase in interstitial fibrosis, composed especially of type-I collagen, in conjunction
Table 2. Receiver operating characteristics, c-statistics and multivariate analysis in ACS and control
compared to TTC.
ACS Control
Area under the curve (95% confidence interval)
ROC
MMP-8 0.513 (0.423–0.603) 0.302 (0.216–0.387)*
TIMP-1 0.679 (0.606–0.753)* 0.149 (0.075–0.222)*
MMP-8/TIMP-1 ratio 0.467 (0.378–0.555) 0.413 (0.317–0.509)*
TnT admission 0.522 (0.442–0.602) N/A
C-statistics
Basic† 0.821 (0.764–0.879)* 0.075 (0.041–0.109)*
Basic + MMP-8 0.820 (0.761–0.880)* 0.061 (0.030–0.091)*
Basic + TIMP-1 0.844 (0.783–0.906)* 0.050 (0.020–0.079)*
Basic + MMP-8/TIMP-1 ratio 0.826 (0.767–0.885)* 0.064 (0.033–0.096)*
Odds ratios (95% confidence interval)
Multivariate analysis
MMP-8 and Age, sex, smoking 0.999 (0.996–1.002) 1.009 (1.004–1.013)*
TIMP-1 and Age, sex, smoking 1.012 (1.005–1.018)** 1.053 (1.034–1.072)*
MMP-8/TIMP-1 and Age, sex, smoking 0.759 (0.506–1.138) 6.159 (2.748–13.803)*
MMP-8 and dyslipidemia, hypertension, diabetes† 0.999 (0.996–1.002) 1.008 (1.005–1.012)*
TIMP-1 and dyslipidemia, hypertension, diabetes 1.011 (1.005–1.018)** 1.069 (1.052–1.086)*
MMP-8 and age, sex, smoking, HDL 0.997 (0.994–1.000) 1.010 (1.005–1.015)*
TIMP-1 and age, sex, smoking, HDL 1.009 (1.001–1.017)*** 1.057 (1.035–1.080)*
MMP-8/TIMP-1 and age, sex, smoking, HDL 0.667 (0.434–1.026)*** 8.694 (3.608–20.951)*
ACS, acute coronary syndrome; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MMP-8, matrix
metalloproteinase; ROC, receiver operating characteristics; TIMP-1, tissue inhibitor of matrix
metalloproteinase; TnT, troponin T; TTC, takotsubo cardiomyopathy.
† Basic: age, sex, smoking
* p < 0.0001
** p < 0.01
*** p < 0.05
doi:10.1371/journal.pone.0173371.t002
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with inflammation. MMP-2, MMP-9, and TIMP-3 levels from the biopsies showed elevated
acute MMP-9. The follow-up biopsies after functional recovery show ECM normalization
[13,26]. Acute TTC also exhibits an increased collagen type-I/III ratio, associated with
decreased elasticity and myocardial stiffness [26]. Some of the TTC patients have contraction-
band necrosis similar to that in pheochromocytoma, but lack credible signs of post-ischemic
necrosis [13,26].
Due to decreased proteolysis, ECM accumulates in pressure-overload such as in hyperten-
sive heart-failure patients. Such patients have altered, pro-fibrotic, MMP and TIMP profiles.
The increased amount of fibrosis in the myocardial ECM in these patients affects the left ven-
tricle, both the form and function. Cardiac fibrosis, such as in hypertrophic cardiomyopathy,
linearly associates with regional contractility [27].
Our results showed low levels of MMP-8 in conjunction with elevated TIMP-1 levels in
low-EF TTC patients. The low MMP-8/TIMP-1 molar ratio may reflect reduction in proteoly-
sis and thus increased ECM fibrosis. Considering TTC biopsy data and the previous findings
in heart-failure patients, we suggest that the severity of TTC may be affected by fibrosis due to
low MMP-8 and high TIMP-1 levels. Moreover, stress and neurohumoral activation, including
elevated norepinephrine concentration, affects MMP levels [28,29]. Therefore, in susceptible
patients, a possible catecholamine-induced disruption of the MMP-8/TIMP-1 balance may
lead to a transient increase in myocardial ECM fibrosis, further impairing left-ventricle con-
tractility. Our results showed correlation of MMP-8/TIMP-1 molar ratio with EF in TTC, fur-
ther supporting the connection between fibrosis and left ventricular function.
Unlike in TTC, ACS patients’ EF did not relate to levels of TIMP-1 and MMP-8. Even
though ACS patients and TTC patients with low EF had similar TIMP-1 levels, in contrast to
ACS patients, those TTC patients with low EF had low MMP-8. Therefore, in differentiation
between ACS and TTC, TIMP-1 appears most useful in those with less severe left ventricular
impairment and possibly milder symptoms. Despite similar on-admission TnT values, the
highest values during hospitalization were significantly higher in cases of ACS than of TTC. As
Fig 2. In acute coronary syndrome and Takotsubo Cardiomyopathy (TTC) patients, Matrix Metalloproteinase-8 (MMP-8) and
Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) levels stratified by Ejection Fraction (EF). In TTC, MMP-8 and TIMP-1 levels
also reflect ventricular impairment. Data in box-plots are presented as medians, 25th and 75th percentiles (boxes), and 10th and 90th
percentiles (whiskers). * p = 0.01.
doi:10.1371/journal.pone.0173371.g002
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earlier reported with MMP-1 and MMP-9 [30], the MMP-8 and TIMP-1 showed no correla-
tion with either of the TnT values, suggesting that MMP-8 and TIMP-1 do not describe myo-
cardial damage size. The MMP-8 and TIMP-1, however, did correlate with hsCRP, suggesting
their involvement in the inflammation.
Several reports of atherosclerotic plaques and elevated serum levels of ACS patients impli-
cate MMP-8’s role in the rupture of atherosclerotic plaques. The culprit coronary lesion there-
fore seemed the most plausible source of MMP-8 and TIMP-1 in ACS. In TTC, the earlier
evidence of transient fibrosis associated with inflammation suggested a myocardial source for
the MMP-8 and TIMP-1. Our results support a differing mechanism for the MMP-8 and
TIMP-1 levels in ACS and TTC. Their differing relationship to left ventricle function supports
a different aetiology for the contraction abnormality. Moreover, such a relationship in TTC
may offer an explanation for this varying severity of left ventricle impairment.
Limitations
A larger number of TTC patients would have allowed for more accurate assessment of MMP-
8, TIMP-1, and EF associations and would have further clarified the ability of TIMP-1 in dif-
ferential diagnosis. Furthermore, no left ventriculograms of ACS patients were available,
which prevented direct comparison of cardiac function and MMP-8 and TIMP-1 between
ACS- and TTC patients. More direct proof of MMP-8/TIMP-1 molar ratios’ relation to ECM
fibrosis would have required endomyocardial biopsies of the TTC patients.
Our study design did not allow us to discern whether the kinetics of the enzymes affected
the final results. Even though the serum samples were taken in the acute phase, the time-lapse
information from pain-to-blood sample was lacking. Moreover, serial sampling was impossi-
ble. Previously, serial samples of ACS patients after myocardial infarction revealed a dynamic
quality in the circulating levels of MMP-8, MMP-9, and TIMP-1 in both the acute and the
recovery period [31,32]. Such a finding warrants further prospective TTC studies with serial
samples.
Conclusions
Acute-phase TIMP-1 superseded other differing factors and improved the ability of TnT in dif-
ferentiation between ACS and TTC. In TTC, a pro-fibrotic low MMP-8/TIMP-1 molar ratio
correlated with low EF, which could reflect the previously reported transient fibrosis in endo-
myocardial biopsies. We suggest that the possible fibrotic accumulation of ECM might explain,
in some TTC patients, their more severely impaired left ventricular function.
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